WAITING LIST FOR LIVER TRANSPLANTATION: CLINICAL AND ECONOMIC BURDEN.

BACKGROUND: Burden of disease is an indicator that relates to health status. United States and European epidemiological data have shown that the burden of chronic liver disease has increased significantly in recent decades. There are no studies evaluating the impact of complications of chronic liver disease on the waiting list for deceased donor liver transplantation (LTx). OBJECTIVE: To determine the clinical and economic burden of complications of liver disease in wait-listed patients from the perspective of a transplant center. METHODS: The study retrospectively analyzed medical records of 104 patients wait-listed for deceased donor LTx from October 2012 to May 2016 and whose treatment was fully provided at the study transplant center. Clinical data were obtained from electronic medical records, while economic data were collected from a hospital management software. To allocate all direct medical costs, two methods were used: full absorption costing and micro-costing. RESULTS: The most common complication was refractory ascites (20.2%), followed by portosystemic encephalopathy (12.5%). The mean number of admissions per patient was 1.37±3.42. Variceal hemorrhage was the complication with longest median length of stay (18 days), followed by hepatorenal syndrome (13.5 days). Hepatorenal syndrome was the costliest complication (mean cost of $3,565), followed by portosystemic encephalopathy ($2,576) and variceal hemorrhage ($1,530). CONCLUSION: The burden of chronic liver disease includes a great cost for health systems. In addition, it is likely to be even greater as a result of the insidious course of the disease.

Lista de espera para transplante hepático: impacto clínico e econômico / Waiting list for liver transplantation: clinical and economic burden

ABSTRACT Background Burden of disease is an indicator that relates to health status. United States and European epidemiological data have shown that the burden of chronic liver disease has increased significantly in recent decades. There are no studies evaluating the impact of complications of chronic liver disease on the waiting list for deceased donor liver transplantation (LTx). Objective: To determine the clinical and economic burden of complications of liver disease in wait-listed patients from the perspective of a transplant center. Methods The study retrospectively analyzed medical records of 104 patients wait-listed for deceased donor LTx from October 2012 to May 2016 and whose treatment was fully provided at the study transplant center. Clinical data were obtained from electronic medical records, while economic data were collected from a hospital management software. To allocate all direct medical costs, two methods were used: full absorption costing and micro-costing. Results: The most common complication was refractory ascites (20.2%), followed by portosystemic encephalopathy (12.5%). The mean number of admissions per patient was 1.37±3.42. Variceal hemorrhage was the complication with longest median length of stay (18 days), followed by hepatorenal syndrome (13.5 days). Hepatorenal syndrome was the costliest complication (mean cost of $3,565), followed by portosystemic encephalopathy ($2,576) and variceal hemorrhage ($1,530). Conclusion: The burden of chronic liver disease includes a great cost for health systems. In addition, it is likely to be even greater as a result of the insidious course of the disease.

RESUMO Contexto O impacto da doença é um indicador relacionado ao estado de saúde. Dados epidemiológicos norte-americanos e europeus mostraram que, nas últimas décadas, o impacto da doença hepática crônica tem aumentado significativamente. Não há estudos que avaliem o impacto das descompensações da doença hepática crônica na lista de espera para transplante hepático (TxH) com doador falecido. Objetivo: Determinar o impacto clínico e econômico das descompensações da doença hepática nos pacientes em lista de espera sob a perspectiva do centro transplantador. Métodos Foram analisados, retrospectivamente, os prontuários de 104 pacientes incluídos em lista de espera para TxH com doador falecido entre outubro de 2012 e maio de 2016 e acompanhados integralmente no centro transplantador. Dados clínicos foram obtidos do prontuário eletrônico, enquanto dados econômicos foram coletados através de software de gestão hospitalar. A apropriação dos custos médicos diretos foi realizada sob duas metodologias: custeio por absorção pleno e microcusteio. Resultados: A descompensação com maior incidência foi a ascite refratária (20,2%) seguida de encefalopatia portossistêmica (12,5%). A média de internações por paciente foi de 1,37±3,42. A hemorragia digestiva alta varicosa foi a descompensação com maior tempo mediano de internação (18 dias), seguida da síndrome hepatorrenal (13,5 dias). A descompensação mais onerosa foi a síndrome hepatorrenal (custo médio de US$ 3.565), seguida encefalopatia portossistêmica (US$ 2.576) e a hemorragia digestiva alta varicosa (US$ 1.530). Conclusão O impacto da doença hepática crônica inclui um custo importante para os sistemas de saúde. Além disso, é provável que seja ainda maior em decorrência do curso insidioso da doença.

Multivariate risk and clinical signs evaluations for early-onset sepsis on late preterm and term newborns and their economic impact.

There is an increasing evidence that strict evaluation of clinical signs is effective in detecting newborns at risk of early-onset sepsis (EOS) that require antibiotic therapy. In a retrospective case control design, we compared EOS antibiotic indication by clinical signs surveillance with multivariate risk analysis (EOSCalc), and estimate their costs. Newborns ≥ 34 weeks who received EOS antibiotics from June 2014 to December 2016 were studied. Were considered symptomatic those with three clinical signs within first 24 h or two signs and one risk factor present. Cost estimative was done using bottom-up hospital's perspective. Eight thousand three hundred twenty-one were born, 384 were included. Two hundred nineteen (57%) would receive antibiotics by EOSCalc and 64 (16.7%) by clinical signs (p < 0.001). All patients with blood cultures were detected and false-negatives were absent. Total cost was US$ 574,121, estimate US$ 415,576 by EOSCalc, and US$ 314,353 by clinical signs (p < 0.001).Conclusions: The use of EOSCalc and clinical signs surveillance seem to be safe and accurate methods in EOS management. Additionally, the two approaches have shown an economic advantage when compared with the hospital's current practice. What is Known: • EOSCalc is a useful method for screening of EOS in late preterm and term infants. • Presence of clinical signs and/or maternal risk factors are present newborns with EOS. What is New: • Rigorous observation of clinical signs is a more accurate method than EOSCalc to screen for EOS in late preterm and term newborns. • Rigorous observation of clinical signs is more economic than EOSCalc in managing EOS in late preterm and term neonates.

Drug-Related Morbidity in Brazil: A Cost-of-Illness Model.

OBJECTIVES: To estimate the proportion of patients with drug-related morbidities (DRMs), DRM preventability, and the cost of illness of the DRMs in Brazil. METHODS: We used the decision-analytic model initially developed by Johnson and Bootman (Drug-related morbidity and mortality. A cost-of-illness model. J Manag Care Pharm 1996;2:39-47), which was adapted to the reality of the present study. A hypothetical cohort of patients in ambulatory care setting was simulated considering the perspective of the Brazilian public health system. Direct costs related to health care were obtained from the national databases, and the probability of occurrence of DRMs was established by a panel of clinical experts. Sensitivity analyses were conducted. RESULTS: An estimated 59% ± 14% of all patients assisted by the health system suffer some DRMs. Given these cases, 53% ± 18% were considered preventable. The average cost of managing a patient with any DRM was US $155. The cost of illness of the DRMs in Brazil would account for nearly US $18 billion (US $9-$27 billion) (best and worst case scenarium) annually. This amount is 5 times higher than what the Ministry of Health spends to guarantee free medicines in Brazil. Hospitalizations and long-term stays in hospital correspond to 75% of this cost. The sensitivity analysis showed that the model is sensitive to variations in these two outcomes. CONCLUSIONS: According to the model, a large proportion of patients experience DRM and the economic impact to solve these problems is substantial for the health system. Considering that more than half of these cases are preventable, it could be possible to achieve an enormous saving of resources through actions that improve the process of medication use.

Função de Produção de Saúde para o Rio Grande do Sul em 2008 / Health Production Function for the Rio Grande do Sul in 2008

Objetivo: estimar uma função de produção de saúde para indivíduos adultos entre 25 e 85 anos que residem no Estado do Rio Grande do Sul, utilizando a base de dados da PNAD (2008), através de estimações de modelos Probit. Busca-se entender qual a relação entre as variáveis analisadas no estudo com o estado de saúde da população e quais suas implicações para a formulação de políticas públicas. Uma função produção de saúde é a relação entre insumos e produtos, ou seja, entre assistência médica, serviços de saúde e estado de saúde da população. Resultados: Observou-se uma associação positiva entre saúde e escolaridade. Entre os que possuem zero ano de escolaridade, 59% são saudáveis, já entre as pessoas com 15 anos de escolaridade, esse percentual é de 92%. Encontrou-se também que, quanto maior a idade, menor a proporção de indivíduos com saúde boa ou muito boa. Na faixa de idade entre 25 e 34 anos, 88% são saudáveis, enquanto na faixa de 60 anos ou mais, esse número se reduz para 53%. Conclusão: As principais conclusões deste trabalho foram que maiores níveis de escolaridade e renda, menores níveis de idade, residir na área urbana, ser do sexo masculino, possuir internet, não fumar e praticar exercício físico estão associados a uma melhor saúde do indivíduo. Observou-se que o efeito da educação sobre a saúde é maior para as mulheres; já a renda domiciliar per capita mostrou-se significativa apenas para a amostra do sexo masculino.

Objective: estimate health production function for adults ranging from 25 to 85 years old, living in the state of Rio Grande do Sul, making use of the National Household Survey Database (2008), by estimations of Probit model. The goal is to understand the relationship between the variables analyzed in the study with the health status of the population and their significances for the formulation of public policies. Health production function means the relationship between inputs and outputs, that is, between medical care, health care, and health status of the population. Results: There was a positive association between health and education. Among those with zero year of schooling, 59% are healthy, as among people with 15 years of schooling, this percentage is 92%. It was found also that the greater the age, the lower the proportion of individuals with good or very good health. Since the age group between 25 and 34 years, 88% are healthy, while in the range of 60 years or more, this number is reduced to 53%. Conclusion: The main conclusions were that higher level of education and income, lower age, residence in urban areas, male gender, internet access, no smoking, and physical exercise practice are linked with better health of the individual. It was noticed that the effect of education over health is higher for women, since the per capita household income proved to be meaningful only for the male gender sample.

Cost-effectiveness of whole-body bone scans in the pre-liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil.

BACKGROUND: Bone metastases (BM) are rare in patients with early-stage hepatocellular carcinoma (HCC). In many centers, liver transplantation (LTx) policies require patients with HCC to undergo bone scans (BSs). METHODS: We retrospectively assessed the benefit of BS for patients with a diagnosis of HCC wait-listed for LTx. RESULTS: BS was performed in 259 of 328 patients (78.9%) and was suggestive of BM in only one (0.4%). At follow-up, 276 patients had received LTx, of whom 207 had undergone BS. Histopathological examination of explants failed to confirm the presence of HCC in 20 patients from the BS group. The survival and recurrence rates of the 187 patients with confirmed HCC in the explant who underwent BS as part of pre-LTx assessment and 69 patients who did not undergo BS were compared. The one- and five-yr post-transplant survival rates were 81% and 69%, respectively, in the BS group vs. 78% and 62%, respectively, in patients who did not undergo BS (p = 0.25). The one- and five-yr post-LTx recurrence rates were 4.8% and 10.7%, respectively, in the BS group vs. 2.9% and 10.1%, respectively, in patients who did not undergo BS (p = 0.46). CONCLUSIONS: BS generated expenditures of US$39 296 and was not cost-effective.

Análise dos incentivos contratuais de transplantes de rins no Brasil pelo modelo agente-principal / Analysis of contractual incentives for kidney transplants in Brazil using the principal-agent model / Análisis de los incentivos contractuales de trasplantes de riñón en Brasil mediante el modelo agente-principal

Resumo: O objetivo do artigo foi analisar os incentivos contratuais de transplantes renais no Brasil com base no modelo agente-principal. A abordagem assume que o Ministério da Saúde seja o principal e os hospitais públicos credenciados pelo Sistema Nacional de Transplantes sejam o agente. O bem- estar do Ministério da Saúde depende das ações tomadas pelos hospitais captadores desse órgão. Os hospitais alocam esforços administrativos, financeiros e gerenciais para realizar as ações de doação, remoção, captação e transplante de rim. Os hospitais podem escolher os níveis de esforços que são compatíveis com os pagamentos e incentivos recebidos referentes ao custeio de transplantes. A solução para esse tipo de problema está na estruturação de um contrato ótimo de incentivos, no qual se requer um alinhamento de interesses de ambas as partes envolvidas nesse sistema de transplantes.

Abstract: The aim of this article was to analyze contractual incentives for kidney transplants in Brazil based on the principal-agent model. The approach assumes that the Brazilian Ministry of Health is the principal and the public hospitals accredited by the National Transplant System are the agent. The Ministry of Health's welfare depends on measures taken by hospitals in kidney uptake. Hospitals allocate administrative, financial, and management efforts to conduct measures in kidney donation, removal, uptake, and transplantation. Hospitals may choose the levels of effort that are consistent with the payments and incentives received in relation to transplantation costs. The solution to this type of problem lies in structuring an optimal incentives contract, which requires aligning the interests of both parties involved in the transplantation system.

Resumen: El objetivo del artículo fue analizar los incentivos contractuales de trasplantes renales en Brasil, a partir del modelo agente-principal. Este enfoque asume que el Ministerio de Salud sea el principal y los hospitales públicos, autorizados por el Sistema Nacional de Trasplantes, sean los agentes. El bienestar del Ministerio de Salud depende de las acciones tomadas por los hospitales receptores de este órgano. Los hospitales proporcionan los esfuerzos administrativos, financieros y de gestión para realizar las acciones de donación, extirpación, recepción y trasplante de riñón. Los hospitales pueden escoger los niveles de esfuerzos que son compatibles con los pagos e incentivos recibidos, referentes al costeo de trasplantes. La solución para este tipo de problema está en la estructuración de un contrato óptimo de incentivos, en el que se requiera un alineamiento de intereses de ambas partes involucradas en este sistema de trasplantes.

[Efficiency of Brazilian States and the Federal District in the public kidney transplant system based on DEA (Data Envelopment Analysis) and the Malmquist index]. / Eficiência dos estados brasileiros e do Distrito Federal no sistema público de transplante renal: uma análise usando método DEA (Análise Envoltória de Dados) e índice de Malmquist.

The objective of this study was to evaluate the efficiency of Brazilian States and the Federal District in the public kidney transplant system and their productivity trends from 2006 to 2011. The authors used Data Envelopment Analysis (DEA) with slack and the Malmquist index with slack. Inputs included spending on hospital services and health professionals in the system. The output was the number of kidney transplants performed in each State. The data showed a significant discrepancy between States in the number of kidney transplants. The transplant system's inefficiency may result from inadequate management, failure to comply with national guidelines, inactive hospital transplant committees, and overburdened hospital staff. Institutional changes promoted by the Brazilian Ministry of Health (procedures improvement and standardization) failed to increase productivity in most States during this period.

Eficiência dos estados brasileiros e do Distrito Federal no sistema público de transplante renal: uma análise usando método DEA (Análise Envoltória de Dados) e índice de Malmquist / Efficiency of Brazilian States and the Federal District in the public kidney transplant system based on DEA (Data Envelopment Analysis) and the Malmquist index / Eficiencia de los estados brasileños y el Distrito Federal en el sistema público de trasplante de riñón: un análisis utilizando el procedimiento DEA (Análisis de Involucrados de Datos) e índice Malmquist

O objetivo foi avaliar a eficiência dos estados brasileiros e do Distrito Federal no sistema público de transplante renal e a mudança de produtividade deles entre 2006 e 2011. Utilizou-se a Análise Envoltória de Dados (DEA) baseada em folgas e o índice de Malmquist com folgas. Os inputs usados foram os gastos dos serviços hospitalares e dos profissionais no sistema. Como output, o número de transplantes renais realizados por cada estado. Existe uma discrepância significativa em relação à captação e ao número de transplantes renais entre os estados. Evidencia-se uma ineficiência nesse sistema, que poder ser causada por sua gestão inadequada; não seguimento de regras nacionais; comissões intra-hospitalares não ativas e equipes hospitalares sobrecarregadas. As mudanças institucionais promovidas pelo Ministério da Saúde (aperfeiçoamento e padronização dos processos) não geraram aumento de produtividade na maioria dos estados nesse período.

The objective of this study was to evaluate the efficiency of Brazilian States and the Federal District in the public kidney transplant system and their productivity trends from 2006 to 2011. The authors used Data Envelopment Analysis (DEA) with slack and the Malmquist index with slack. Inputs included spending on hospital services and health professionals in the system. The output was the number of kidney transplants performed in each State. The data showed a significant discrepancy between States in the number of kidney transplants. The transplant system’s inefficiency may result from inadequate management, failure to comply with national guidelines, inactive hospital transplant committees, and overburdened hospital staff. Institutional changes promoted by the Brazilian Ministry of Health (procedures improvement and standardization) failed to increase productivity in most States during this period.

El objetivo fue evaluar la eficacia de los estados brasileños y en el Distrito Federal en el trasplante renal público y su productividad entre 2006 y 2011. Se utilizó el Análisis de Involucrados de Datos (DEA) y el índice de Malmquist. La muestra estuvo conformada por 22 estados. Las entradas corresponden a los gastos totales de trasplantes de riñón, referidos a servicios generales y hospitalarios de los profesionales de este sector. Se utilizó el número de riñones trasplantados como punto de salida. Entre los estados existe una discrepancia significativa, en relación con la captación y el número de trasplantes de riñón. Es evidente la ineficiencia del sistema, que puede ser causada por la gestión de operaciones inadecuadas, el incumplimiento de las normas nacionales, los comités no hospitalarios y personal hospitalario activo sobrecargado. Sin embargo, su productividad ha mejorado con los cambios institucionales. Por lo tanto, los estados que participaron en el proceso de recepción y donación de riñones para trasplantes presentan ineficiencia en términos de gastos administrativos y operativos.

Cost-effectiveness of the vaccine against human papillomavirus in the brazilian Amazon region / Custo-efetividade da vacina contra o papilomavírus humano na região Amazônica brasileira

OBJECTIVE: To assess the cost-utility of the human papillomavirus (HPV) vaccination on the prevention of cervical cancer in the Brazilian Amazon region. METHODS: AMarkov cohort modelwas developed to simulate the natural evolution of HPV and its progress to cervical cancer, considering the current preventive programs and treatment costs. The one-year transition probabilities were mainly based on empirical data of local and national studies. The model evaluated the addition of the vaccine to three cervical cancer-screening scenarios (0, 3 or 10 exams throughout life). RESULTS: The scenario of three Pap tests resulted in satisfactory calibration (base case). The addition of HPV vaccination would reduce by 35% the incidence of cervical cancer (70% vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each quality-adjusted life year gained. The sensitivity analysis confirms the robustness of this result, and duration of immunity was the parameter with greater variation in incremental cost-effectiveness ratio. CONCLUSION: Vaccination has a favorable profile in terms of cost-utility, and its inclusion in the immunization schedule would result in a substantial reduction in incidence and mortality of invasive cervical cancer in the Brazilian Amazon region.

OBJETIVO: Avaliar a custo-efetividade da vacinação contra o papilomavírus humano (HPV) na prevenção do câncer de colo de útero na região Amazônica brasileira. MÉTODOS: Um modelo de coorte Markov foi desenvolvido para simular a história natural do HPV e seu progresso para câncer de colo de útero, considerando os atuais programas de prevenção e os custos de tratamento. As probabilidades de um ano de transição foram baseadas principalmente em dados empíricos de estudos locais e nacionais. O modelo avaliou a adição da vacina a três cenários de rastreio de câncer de colo de útero (0, 3 ou 10 exames ao longo da vida). RESULTADOS: O cenário de três exames de Papanicolau resultou em calibração satisfatória (caso base). A adição de vacinação contra o HPV reduziria em 35% a incidência de câncer de colo de útero (70% de cobertura de vacinação). A razão incremental de custo-efetividade foi US$ 825 para cada ano de vida ajustado para qualidade ganho. A análise de sensibilidade confirma a robustez deste resultado, e a duração de imunidade foi o parâmetro com maior variação na razão incremental de custo-efetividade. CONCLUSÃO A vacinação tem um perfil favorável em termos de custo-utilidade, e sua inclusão no calendário de imunização resultaria em redução substancial de incidência e de mortalidade relacionadas ao câncer de colo de útero na região Amazônica brasileira.

An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System.

OBJECTIVES: Hepatitis C therapy in Brazil is expensive due to the cost of antiviral drugs and demands on medical resources. The objective of this study was to estimate the direct costs per patient of chronic hepatitis C therapy in a Brazilian setting. METHOD: A microcosting study from a public health system perspective. The costs included were those of antiviral drugs, secondary medicines, diagnostic tests, visits to physicians and other professionals, hospitalization, nurse, and pharmaceutical care. All costs were priced in 2010. The values were converted to US $ (2010). RESULTS: The total direct cost of hepatitis C treatment per patient with interferon alpha (IFN) plus ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180 µg plus RBV was US $10,658.08, and with PEG 2b 120 µg plus RBV was US $12,597.63, taking into account entire treatment according to Brazilian guidelines and assuming that all patients completed full treatment. The antiviral drugs are the most expensive element of the cost of treatment, totaling more than 40% of the medical costs of IFN plus RBV therapy and more than 88% of PEG plus RBV therapy. Calculating an average of 10,000 treatments per year, the total direct cost is US $90,346,772.39. According to the Ministry of Health, 90% of the annual total cost of hepatitis C treatment is accounted for by antiviral drugs. CONCLUSIONS: In Brazil, antiviral drugs are the most expensive component of hepatitis C treatment. The cost of follow-up and support to patients is minimal compared with the cost of antiviral drugs.

Estimando as perdas de rendimento devido a doença renal crônica no Brasil / Estimating earning losses due to chronic renal disease in Brazil

O artigo tem como objetivo principal estimar as perdas de rendimentos individuais devido a doença renal crônica. A partir de dados da Pesquisa Nacional de Amostras de Domicílios (PNDA/1998) são estimadas as perdas de rendimento através dos métodos dos mínimos quadrados ordinários e de regressão quantílica, que permite medir o impacto da doença sobre os rendimentos, ao longo da distribuição do salário no Brasil. Os resultados indicaram que os mais pobres têm maior redução de rendimento devido à doença crônica, sugerindo que políticas direcionadas para reduzir a incidência da doença renal crônica podem contribuir para a redução de desigualdade de rendimento